The Oncology KnowledgeBASE provides a comprehensive view of the status of the global oncology drug development and personalized medicine sector in terms of:
- companies developing and marketing therapeutics/in vivo imaging agents and/or in vitro diagnostics
- institutions/non-profits with affiliations/agreements in this sector
- therapeutic agents in development or on the market globally (over 4,500 drugs in development)
- molecular targets of approved drugs and of those currently evaluated in preclinical/clinical trials or identified as playing a role in cancer
- patents, orphan drug status, sales, etc.
New Drugs and Marketed Drugs profiles
The database provides detailed profiles of over 4,500 distinct drugs/in vivo imaging agents in development and on the market by:
- developer/affiliate (over 1,000 pipelines)
- generic name/brand name/other designation
- mechanism of action
- cancer indications; over 100 indications
- clinical indications; hundreds of indications
- administration route
- molecular targets
- biomarker/companion diagnostics
- delivery technology
- development status
- clinical development by phase and status
- clinical history, including trial protocols, interim and final results
- sales history (when available)
The database profiles over 2000 companies in the oncology space in terms of:
- enabling technologies
- pipelines, etc.
Targets in Oncology Profiles
The database profiles over 1,000 molecular targets implicated in cancer and its treatment in terms of:
- cancer indication
- utility (treatment, in vivo imaging, in vitro diagnosis, prognosis, disease monitoring
- institution/academic programs
Who should subscribe to the Oncology KnowledgeBASE:
Researchers (Academic and Industrial)
The oncology sector dominates the global R&D and clinical development efforts. Over 50,000 academics in the USA are working in the life sciences field and most are in some way involved in cancer. In addition, thousands are working in the industry. Similarly, academics in every major country in the world are working in the cancer area. A cursory review of PubMed (ncbi.nlm.nih.gov/pubmed), the depository of all peer-reviewed journal articles originating around the world, readily informs that the largest share of the publications relates to oncology issues with many coming from abroad, particularly China.
About 14,000 oncologists practice in the USA and thousands more globally.
- Clinical Research Organizations (CRO)
- Government regulatory agencies
- Government Institutes
- Enabling technology companies (big data, sequencing, product development, preclinical development)
- Investors (venture funds, Wall Street firms, etc.)
Oncology KnowledgeBASE is a relational knowledgebase covering all major aspects of product development in oncology. The database comprises 6 modules each dedicated in a specific sector within the oncology field. Use the keyword option or the query screen within each module to find the data sought. Entries are cited with links to the origin of the data when appropriate. As a relational resource, nm|OK allows the user to retrieve comprehensive data along numerous lines of inquire as described below.
New and Marketed Drugs Module
These modules comprise comprehensive records of thousands of drugs in discovery/research, preclinical and clinical development and those on the market globally. Numerous possible inquiries within these modules include:
- Individual company pipelines
- Company affiliations
- Marketed or novel drugs by target (and by indication, clinical status, technology, mechanism, delivery, etc.)
- Marketed or novel drugs by mechanism (cytotoxics, immunotherapy agents, angiogenesis inhibitors, apoptosis enhancers, gene silencing agents, oncolytics, etc.)
- Marketed or novel drugs by technology (small molecule drugs, monoclonal antibodies, antibody-drug conjugates, immune-oncology agents, fusion proteins, synthetic nucleic acid sequences and RNAi, radioimmunoconjugates, etc.)
- Marketed or novel drugs by drug delivery (liposomes, nanoparticles, PEG, vectors, etc.)
- Marketed or novel drugs by indication (100 different cancer indications and over 2000 clinical indications)
- Novel drugs by phase of clinical development (clinical trials described for over 2000 novel agents, with interim and final results when appropriate)
- Biomarkers associated with the development of new drugs (over 2,160 targeted drugs in clinical/preclinical development
- Marketed drugs by approved indication (over 530 branded drugs)
This module profiles thousands of companies spanning the spectrum of small start-ups to multinational biotechnology and pharmaceutical companies developing drugs and personalized medicine tools or providing enabling technologies in this sector. Possible inquiries within these modules include:
- Full address, list of company executives, website links, etc.
- Financings, IPO, mergers, and acquisitions
- Description of enabling technologies
- Affiliations and collaborations worldwide
- Diagnostics/personalized medicine products and services by cancer indication (diagnostics, prognostics, theranostics, disease monitoring methodologies, pharmacogenomics, etc.)
Targets in Oncology Module
This module profiles over 1000 molecular markers relevant in personalized medicine. Numerous possible inquiries within these modules include:
- Marker profile (name, location, description,
- Markers by cancer indication (over 100 indications)
- Markers by expression site (secreted, cell membrane. intracellular, cytoplasm, nucleus, cytosol, etc.)
- Markers incorporated in vitro testing (IVT) assays
This module includes reports covering unique aspects of the oncology sector often related to government, academic, or nonprofit activities that may impact the science and or delivery of cancer-related care.
This is a free access list of 1,280 terms related to every aspect of the oncology sector including organizations, associations, government agencies and programs, terms, measures, etc. It serves as a means of deciphering the various acronyms used to describe various interventions in this sector.